Stock 9969 INNOCARE PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages InnoCare Pharma Limited

Equities

9969

KYG4783B1032

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:22 29/04/2024 BST 		5-day change 1st Jan Change
4.51 HKD +1.35% Intraday chart for InnoCare Pharma Limited +11.08% -34.54%
03-29 InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib CI
03-28 Transcript : InnoCare Pharma Limited, 2023 Earnings Call, Mar 28, 2024

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
InnoCare Pharma Limited Reports Earnings Results for the Full Year Ended December 31, 2023
InnoCare Pharma Limited Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China
InnoCare to Shrink Loss in 2023
InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023
InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China
InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area's Early Access Program
InnoCare Pharma Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA
InnoCare Pharma Limited Announces the Positive Top-Line Results from the Phase II Randomized, Double-Blind, Placebo-Controlled Study of ICP-332
InnoCare Pharma Announces Latest Data of Oncology Pipelines Presented at the 65th Annual Meeting of ASH
InnoCare Pharma Limited Reports Earnings Results for the Nine Months Ended September 30, 2023
InnoCare Pharma Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China
Innocare Pharma Limited Announces the Appointment of Dandan Dong as Independent Non-Executive Director
InnoCare Pharma Limited commences an Equity Buyback Plan for 149,967,323 shares, representing 8.5% of its issued share capital, under the authorization approved on June 2, 2023.
InnoCare Pharma Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib
InnoCare Announces Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology
InnoCare Pharma's Loss Narrows in H1; Shares Down 4%
InnoCare Pharma Limited Reports Earnings Results for the Half Year Ended June 30, 2023
Innocare Pharma Limited Announces Board Changes
InnoCare Pharma and ArriVent Biopharma Announce Clinical Development Collaboration
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 9969 Stock
  4. News InnoCare Pharma Limited
  5. Other languages